Filing Flows › Health Care › Century Therapeutics (IPSC)
Century Therapeutics (IPSC) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 15, 2025 · Century Therapeutics (IPSC) Q1 2025 earnings results →
Q1 2025 Revenue up 12668% year over year to $109M · 70¢ of every $1 of revenue kept as net profit · operating margin 67.9%
Century Therapeutics made $109M in Q1 2025 (128× Y/Y). Operating margin 67.9%, net earnings $76.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 15, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $109.2M in Q1 2025, up 12668% year over year and up 2516% from the previous quarter.
Operating profit was $74.2M, a 67.9% margin (up 3729.8 points year over year). Total costs grew 9% against revenue growth of 12668%. The fastest-growing cost line was Research & development (+13%). Net earnings were $76.6M. The effective tax rate was 0.0%.
Operating cash flow was −$34.6M. Non-cash charges added back $3.2M of depreciation and $2.4M of share-based compensation. Working capital and other items used $116.8M. Capital expenditures of $475K exceeded it, leaving free cash flow of −$35.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 15, 2025 | $109M | 128× | 67.9% | $76.6M | −$34.6M |
| Q4 2024 | 10-K | Mar 19, 2025 | $4.2M | 16× | -893.5% | −$36.1M | −$24.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Century Therapeutics
We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. As a result, we believe such “off-the-shelf" therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population.
In its own words, from its 10-K, filed Mar 12, 2026.
Century Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 128× against the peers' median +29%. Operating margin: 67.9% against the peers' median 40.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IPSC Century Therapeutics | Q1 2025 | $109M | 128× | 67.9% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Century Therapeutics 10-Q on SEC EDGAR · CIK 1850119 · Biological Products, (No Diagnostic Substances)
13F: who owns IPSC and who is buying
More on IPSC
- How Century Therapeutics makes money: revenue by segment
- Century Therapeutics next earnings date and what analysts expect
- Century Therapeutics stock forecast, price target and fair value
- Who owns Century Therapeutics stock: holders, funds and Congress trades
- Century Therapeutics recalls, complaints and regulation
History
Every quarter: Q1 2025 results · Q4 2024 results